Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis
Fig 2
Risk of bias for the eligible studies.
Risk of bias legend: A = random sequence generation; B = allocation concealment; C = blinding of participants and personnel; D = blinding of outcome data; E = incomplete data; F = selective reporting; G = other bias. ahigh risk of bias was expected for the assessment of adverse events; the risk of bias was lower for efficacy outcomes due to the objective methods of assessment. bA high risk of bias was expected for the reporting of adverse events. cStudy contained a larger proportion of women > 40 years of age in the oral dydrogesterone group. dSingle-blind study. eDouble-blind study, but patients were aware of the treatment arm due to the different routes of administration and the lack of use of a placebo dummy. fOpen-label study. g10.3% participants were excluded after randomization, and the numbers lost to follow-up were unbalanced between treatment groups. hDouble-blind, double-dummy study.